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ABSTRACT
Background: According to the American Cancer Society, lung cancer was accountable for over 142,000
deaths in the USA in 2019. Common mutations related to lung cancer mainly occur in TP53, EGFR, and KRAS
genes. Lapatinib is a small molecule tyrosine kinase inhibitor which acts reversibly on both epidermal growth
factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). Overexpression of EGFR leads
to increased production and signaling of proteins that cause upregulation of cellular proliferation,
cholesterol synthesis and resistance to apoptosis. Ketoconazole is an imidazole antifungal agent which works
principally by inhibiting the enzyme cytochrome P450 14α-demethylase (CYP51A1) in the fungal cell
membrane. A recent study showed that ketoconazole can reduce cholesterol synthesis in the mitochondria
of lapatinib resistant lung cancer cells. The use of lapatinib in combination with ketoconazole has shown
promises to work against therapeutic resistance in that study but as these drugs have limited oral
bioavailability, the clinical applicability of this therapeutic approach is highly questionable. So, there is a
need to explore a suitable delivery strategy for this combination therapy to achieve its full potential.
Methods: Both lapatinib and ketoconazole are poorly water soluble, which is responsible for their variable
oral absorption. Large daily doses of lapatinib limit its clinical usage significantly due to the occurrence of
various side effects. Nanoparticle based formulations offer remarkable promise in delivering hydrophobic
drugs and enhancing their permeability and retention (EPR) inside tumors. In this study, a PEGylated
hyaluronic acid (PEG - Polyethylene glycol) coated lipid micellar nanoparticle has been developed using a
thin film hydration procedure for combined delivery of lapatinib and ketoconazole in cancer cells.
Characterization of the particles including, in vitro drug release, cellular uptake, and cell viability studies have
been performed to assess their functionality as a cancer drug delivery vehicle.
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Results: Size and zeta potential of the particles were 170 nm and 16 mV respectively with a narrow size
distribution which also exhibited good colloidal stability over a month. Drug loading data obtained using
HPLC revealed 70% loading efficiency for lapatinib and 100% for ketoconazole. In vitro data showed
augmented cellular toxicity of this lipid particle compared to free drugs in H1650 and LLC1 cells. Besides drug
release study performed at pH 7 and 5 in the presence and absence of hyaluronidase (HAase) and cellular
uptake of the particles studied using H1650 cells also have been found to be satisfactory. Particle showed an
initial burst release of drugs in presence of HAase which is desirable for chemotherapeutic drug delivery in
tumor site which is rich in HAase.
Conclusion: HA coated lipid micellar nanoparticle can be a promising tool for delivery of lipophilic drugs like
lapatinib in combating drug resistance.

viii

CHAPTER ONE
INTRODUCTION
Cancer
Cancer is the second largest cause of mortality in the United States after heart diseases. According to Centers
for Disease Control and Prevention (CDC), the number of deaths has been anticipated to rise 15 % in men
and 8 % in women between the year of 2007 and 2020. Cancer is an umbrella term used to define conditions
when cells lose their normal control mechanism causing abnormal proliferation and differentiation mostly
due to genetic mutations. These types of mutations may be rooted in overexpression or formation of novel
oncogenes, which promote cell growth and reproduction, or deregulation of tumor suppressor genes.
Normally, human cells have an orderly process which maintains cell division and apoptosis. However, this
system breaks down when cancer develops, and body starts amassing cells without sheading them off
resulting in the formation of tumors. Tumors can be benign or malignant depending on their invasiveness,
which can determine the level of fatality.
Carcinogenesis can begin with a single genetic defect, but it doesn’t start abruptly, rather it is a multistage
process gradually accumulating defects in the cell growth regulatory system up to the point that body’s
defense mechanism fails to repair the damages. Unlike normal cells, cancer cells ignore the signals for
programmed cell death, divide spontaneously, and influence nearby non-cancerous cells to form new blood
vessels and thus increase supply of nutrient and oxygen into that region eventually forming a core
surrounded by a distinct tumor microenvironment.
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Lung Cancer
Up till now, more than 100 different types of cancers have been categorized (National Institute of Cancer).
Cancers are usually named after the organ or tissue where they initially form. In Lung cancer, as its name
suggest starts in the cells of the lungs. The lungs are two sponge like organs in the chest comprised of three
lobes. The right lung has three sections or lobes and the left lung has two lobes which are smaller in size due
to the presence of the heart. Air enters through the nose and goes into the lungs through the trachea or
windpipe. Inside the lungs, the trachea gets bifurcated into two bronchi which further divide to form smaller
branches called bronchioles. At the end of each bronchiole there are tiny air sacs known as alveoli. These
alveoli interact with the surrounding blood vessels and facilitate oxygen and carbon di oxide transport
between the lung and blood. Lung cancers usually starts in the cells lining the bronchi, bronchioles, or
alveolar regions.
Lung cancer as a reportable disease, was seemingly very rare before the 20th century and has evolved
drastically since the last century, becoming the deadliest form of cancer (Spiro and Silvestri 2015). The
American Cancer Society’s has estimated about 228,820 new cases of lung cancer in the United States for
2020 among which 116,300 will be in men and 112,520 will be in women, which is around 13% of the total
cancer cases projected. In 2017, lung cancer caused more deaths than breast, colorectal, prostate and brain
cancers added together (Siegel et al., 2020). Cigarette smoking is the main underlying causes of lung cancer.
In 1929 the German physician, Fritz Lickint first indicated an association between lung cancer and smoking
in one of his paper. He is the pioneer of antitobacco activism, which was widespread during that time in
Germany. In United States, smoking has been declining since 1964, when the first Surgeon General’s report
was published highlighting its impact on public health (Witschi, 2001). There are many other risk factors
related to lung cancers, including heredity, prior pulmonary diseases such as chronic obstructive pulmonary
disease (COPD) or tuberculosis, and exposure to radon (a naturally occurring gas), asbestos or secondhand
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smoke, and certain other airborne substances. However, smoking is main cause behind 85%–90% of cases
(Lung cancer in women, Harvard Health Publishing, 2014).
Depending on variation in size and appearance under a microscope, lung cancer can be broadly classified
into two groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Treatment and
outcomes vary depending on this. SCLC often known as oat cell cancer comprises about 10 to 15 % of all lung
cancers. In this type, dense neurosecretory granules are apparent inside the cells which gives the tumor an
association with paraneoplastic syndrome. This mainly begins in the primary and secondary bronchi, which
in 60-70 % cases and can’t be targeted with a single radiation therapy. NSCLC is the most prevalent type of
lung cancer and accounts for 80% to 85% cases. This has three major subtypes: adenocarcinoma, large cell
carcinoma, and squamous cell carcinoma. About 40 percent of all NSCLC occurrences are related to
adenocarcinoma, which originates in the mucus secretory cells of lung. This is usually found in the outer
parts of the lung and early prognosis is much more likely for this type. Squamous cell carcinoma is mostly
found in the central part of the lungs near the adjoining part of the large bronchi to the trachea. This is
accountable for 30% of all NSCLCs. Large cell carcinoma is the fastest growing NSCLC and can be found in any
part of the lung. NSCLC also has some other types i.e. sarcomatoid carcinoma and adenosquamous
carcinoma, which are very rare. (Cancer Treatment Centers of America, 2018) Sometimes, cancers that
originate in other organs can metastasize to lungs, and for those treatment will be based on the primary site
of origin.
Treatment options
Treatment options for lung cancer largely depend on the specific cancer types, however surgery is the main
treatment option. Lung cancer shows no specific symptoms or signs for early detection and most patients
are usually diagnosed with advanced stage (3 or 4) disease. Detections are mainly done with sputum
cytology, thoracentesis, needle biopsy, bronchoscopy, and other tests i.e. endobronchial ultrasound,
3

endoscopic esophageal ultrasound, mediastinoscopy and mediastinotomy, thoracoscopy (American Cancer
Society). Early detection is highly important in preventing lung cancer deaths. The five-year survival rate of
these patients is only 15%, but it rises to 50% when is treated at earlier stage (Lung cancer in women, Harvard
Health Publishing, 2014). Besides surgery, radiation and chemotherapy are given to patients to reduce
recurrence. Some other treatment options emerging for this cancer are immunotherapy, photodynamic
therapy, laser therapy, and targeted therapy.
Chemotherapeutic drugs for lung cancer
Chemotherapy may be recommended in the following situations of NSCLC: neoadjuvant chemotherapy
before surgery, adjuvant chemotherapy after surgery, and chemotherapy for locally advanced and
metastasized (stage 4) NSCLC. Two chemotherapeutic drug combinations are commonly used for early-stage
lung cancer, including cisplatin or carboplatin plus one other drug i.e. Taxol or gemcitabine. In some
instances, gemcitabine with vinorelbine or paclitaxel may also be used. In advanced lung cancer, particularly
people (i.e. elderly) who might not tolerate combination chemotherapy, patients may be treated with a
single chemo drug in addition to a targeted therapy drug such as ramucirumab, bevacizumab or
necitumumab. These drugs are typically given as intravenous injection using central lines, central venous
access devices, or central venous catheters. Chemotherapeutics widely prescribed for lung cancer include
Cisplatin, Carboplatin, Paclitaxel, Albumin-bound paclitaxel (nab paclitaxel), Docetaxel, Vinorelbine,
Gemcitabine, Pemetrexed, and Etoposide.
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Table 1: FDA approved drugs for lung cancer (National Institute of Cancer, 2011):
Drug Classes

Name of drugs

Types of cancer

Platinum based

Cisplatin, Carboplatin

NSCLC

Taxol

Paclitaxel, docetaxel, Abraxane

Antimetabolites

Gemcitabine, Pemetrexed, Methotrexate

Alkylating agent

Mechlorethamine

Vinca alkaloids

Vinorelbine

EGFR TKI

Afatinib, Brigatinib, Dacomitinib, Entrectinib, Gefitinib,

BRAF inhibitors

Lorlatinib, Erlotinib
Dabrafenib

MEK inhibitors

Trametinib

AKL inhibitors

Alectinib, Brigatinib, Ceritinib, Crizotinib

mTOR inhibitors

Everolimus

Monoclonal antibody

Atezolizumab, Bevacizumab, Ramucirumab, Durvalumab,

Drug combination

Pembrolizumab, Necitumumab, Nivolumab
Carboplatin-Taxol, Gemcitabine-Cisplatin

Topoisomerase inhibitor

Doxorubicin, Etoposide, Topotecan Hydrochloride

SCLC

EGFR TKI
Advanced understanding of tumor biology is revealing many biological pathways involved in cellular
abnormal growth, which are differently regulated from normal cells. Epidermal Growth Factor Receptor
(EGFR) gene mutations have been identified as a distinctive feature in many different kinds of tumors,
particularly in lung cancer. EGFR is a cell surface glycoprotein receptor that belongs to a family of receptor
tyrosine kinases and was first identified by Stanley Cohen in 1962 (Sigismund et al., 2018). EGFR has been
found to be overexpressed in 40 to 80 % of all NSCLC patients (Hirsch et al., 2009).
EGFR and its family share a common basic molecular structure, having an extracellular ligand binding
domain, a single transmembrane spanning domain, and an intracellular cytoplasmic domain with a
regulatory carboxyl, C terminal segment (Doebele et al., 2010). Epidermal growth factor binds to the
extracellular domain and causes homo or heterodimerization of the receptor. Receptor dimerization induces
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autophosphorylation of the tyrosine kinase in the cytoplasmic domain, which afterwards causes
phosphorylation of multiple specific intracellular tyrosine residues and eventually initiates several signaling
cascades. These cascades mainly transduce via two different pathways: one is phosphatidyl inositol 3-kinase
(PI3K)-Akt pathway and another one is Ras/Raf/mitogen activated protein kinase pathway (MAPK) (Harris et
al., 2003). These are two widely studied signaling transduction pathways that play a vital role in tumor
proliferation by inhibiting apoptosis and driving cellular growth (Figure 1).

Figure 1: EGFR signaling pathway. Abbreviations: EGFR, epidermal growth factor receptor; ERK,
extracellular signal-regulated kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol
3-kinase
In normal cells, a regulatory mechanism exists to control EGFR activity by mediating endocytosis of
respective ligands and other complexes formed during signaling cascades. This is followed by degradation
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and recycling of the receptor on the cell surface, which ultimately maintains a dynamic balance. In tumor
cells, EGFR mutations and genetic alterations occur leading to persistent activation of downstream signaling
along with altered receptor endocytosis and trafficking to multivesicular bodies, aberrant receptor
ubiquitination, and endo-lysosomal proteolysis, or ligand-independent receptor activation (Critchley et al,
2018). Deletions in exon 19 removes the amino acid motif, LREA and point mutations in exon 21 that replace
arginine with leucine at position 858 (L858R) are responsible for about 85% of EGFR mutations in the NSCLC
and induce EGFR receptor dysfunctionality and oncogenicity (Blakely and Bivona, 2012; Ohashi et al., 2013).
Small molecule tyrosine kinase inhibitors (TKIs) are popular treatment options to manage this upregulation
of EGFR signaling pathway.
Small molecule TKIs bind reversibly or irreversibly with intracellular catalytic domain of EGFR receptor
and inhibit downstream signaling pathway. 1st generation EGFR TKsI, gefitinib, erlotinib and icotinib are
reversible inhibitors of EGFR. Afatinib and dacomitinib are second-generation inhibitors which irreversibly
block EGFR via covalent bondage (Kwapiszewski et al., 2016; Troiani et al., 2016; Wang et al., 2016).
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Figure 2: Mechanism of action of EGFR TKI. TKI, tyrosine kinase inhibitor.
A major limitation of these drugs is that patients develop resistance inevitably after a progression
free period of around 10 months. The two common mechanism causing resistance to these drugs are the
clonal expansion of cancer cells having a point mutation in exon 20 of EGFR which replaces methionine with
threonine at amino acid position 790 of gene domain and cMET amplification (Ma et al., 2011; Ahsan, 2016).
Recently, Osimertinib, a 3rd generation, irreversible EGFR TKI has been granted FDA approval as a highly
efficacious treatment option for NSCLC patients with T790M mutation (Skrzypski et al., 2017). Figure 3
summarizes the EGFR tyrosine kinase inhibitors which are FDA approved for treatment of EGFR over
expressing lung cancer.
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1st
Gefitinib
FDA
approval

2003

FDA
restricted
the use of
Gefitinib.

2004
Discovery of EGFR
mutations. FDA
approved Erlotinib
for metastatic
NSCLC.

2005

FDA
withdrew
Gefitinib
approval.

2010

FDA approved
Gefitinib as 1st
line treatment
for EGFR
mutation.

2012

FDA approved Erlotinib
for switch maintenance
after benefit from 1st
line platinum based
therapy.

2013

2015

FDA approved Afatinib as 1st
line therapy for EGFR mutant
patients. FDA approved
Erlotinib as 1st line treatment
for EGFR mutation.

FDA granted priority review for
dacomitinib as 1st line treatment
for EGFR mutant patient.
FDA approved Afatinib for
uncommon EGFR mutations.

2016
FDA approved
Afatinib as 2nd
line treatment
for squamous
cell lung cancer.

2017

2018

FDA approved 3rd
generation EGFR
TKI Osimertinib
for treatment of
NSCLC.

Figure 3: FDA regulatory approval of first, second and third generation EGFR TKIs through the time
(Karachaliou et al., 2019).
EGFR TKI Resistance and Cholesterol
Lipid raft plays a vital role in intracellular signal transduction, which causes internalization of ligands and
receptors via a process known as raft-dependent endocytosis. These are microdomains within the cell
membrane which are less fluid than the adjacent membrane due to the presence of larger amount of
cholesterol and sphingolipids. Studies shows that lipid raft localization of EGFR intertwines with EGFR TKIs
resistance, resulting in persistent phosphorylation of EGFR (Irwin et al., 2011). However, when cells are
treated with statin drugs, which deplete lipid rafts of cholesterol, they regain sensitivity to EGFR TKI drugs.
This was also evident in a population-based case-control study, which suggests that statin usage in lung
cancer patients on treatment with EGFR TKIs may be related to a lower death rate and improved efficacy of
cancer therapy (Hung et al., 2017). This evidence signifies the importance of regulating cholesterol level in
patients on EGFR TKIs.
Cholesterol plays a role in the mitochondrial induced apoptotic pathway. In this process, upon
receiving apoptotic stimuli, mitochondrial outer membrane permeabilization (MOMP) takes place which
releases mitochondrial intermembrane proteins, notably cytochrome c into the cytosol thereby activating
caspases (Lopez et al., 2015). This MOMP, also known as point of no return, is controlled by the BCL-2 family,
which consists of both pro- and anti-apoptotic proteins. In apoptosis, pro apoptotic BCL-2 proteins, BAX
and/or BAC get activated and interact with the mitochondrial membrane followed by formation of the
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mitochondrial apoptosis induced channel (MAC) to discharge cytochrome c (Dewson et al., 2009). It is
evident that EGFR TKI mediated inhibition of Akt and ERK dependent pathway causes changes in BCL-2
protein expression, thus initiating apoptosis (Birkinshaw et al., 2017) (Figure 4). Several studies have shown
that elevated levels of cholesterol in the mitochondrial membrane may protect the cells against
mitochondrial apoptosis by altering mitochondrial membrane fluidity and permeability which reduces
formation of MAC and the induction of caspases.

Figure 4: EGFR TKI, Mitochondrial Cholesterol, and Apoptosis
Lapatinib and Ketoconazole Combination Therapy
Lapatinib is a 1st generation reversible EGFR TKI commonly used in patients with HER2 (Human Epidermal
Growth Factor Receptor 2) positive metastatic breast cancer because of its dual role as a tyrosine kinase
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inhibitor of both HER2 and EGFR (Esteva et al., 2005). Clinical data support its efficacy in combination therapy
with the EGFR blocking monoclonal antibody trastuzumab and other chemotherapeutic drugs i.e.
capecitabine for breast cancer treatment (Xu et al., 2017; Kaplan et al., 2014). There are studies which imply
lapatinib’s encouraging activity with another anticancer drug, pemetrexed, in NSCLC patients (Ramlau et al.,
2009; Ramalu et al., 2015; GlaxoSmithKline, 2017). However, the development of resistance in patients
remains a major problem.
Ketoconazole is an imidazole antifungal agent which works principally by inhibiting the enzyme
cytochrome P450 14α-demethylase (CYP51A1) in the fungal cell membrane. It is also used in the treatment
of hormone dependent prostate cancer, where it can work as an inhibitor of cytochrome P450 14αdemethylase (CYP17) to reduce adrenal testosterone synthesis which regulates conversion of lanosterol to
cholesterol (Lin et al., 2012; Loose et al., 1983). A recent study in our lab has revealed ketoconazole’s
functionality in arresting cholesterol build up in the mitochondrial membrane, which can help to alleviate
cholesterol associated EGFR TKI resistance (Howell et al., 2020). That study showed that if EGFR TKI resistant
cells are treated with lapatinib in combination with ketoconazole, they regain their sensitivity for lapatinib
which comes with an elevated level of mitochondrial apoptotic activity. (Figure 5) This effect was significant
in cell studies but unfortunately wasn’t fully reflected in mice experiments which presumably was due to the
pharmacokinetic barriers naked drugs have to encounter in animal models not apparent in cell studies.
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Figure 5: Lapatinib and Ketoconazole combination therapy
Nanoformulation of Lapatinib and Ketoconazole
Problems with clinical lapatinib administration include aqueous insolubility, poor oral bioavailability, and
extensive plasma protein binding capacity. Currently, lapatinib is marketed as oral tablet formulation that
must be taken as a large dose daily to obtain desired therapeutic activity. Therefore, it has become
imperative to explore other delivery strategies to maximize its clinical efficacy. Nanotechnology has gained
popularity in drug delivery to resolve common problems encountered by conventional drug delivery system
like poor aqueous solubility, reduced systemic bioavailability, and poor target specificity (Kemp et al., 2016;
Gulati et al., 1998).
Lapatinib is a BCS (Biopharmaceutics Classification System) class II drug having low water solubility
(7 μg/mL), which compromises its dissolution in gastrointestinal tract followed by irregular absorption and
diminished plasma drug concentration (Bonde et al., 2018). Bioavailability has been found to be elevated
12

when taken with high fat diet compared to fasting condition. Besides, in systemic circulation 99% of the drug
gets bound to plasma protein which further reduces its availability at the tumor site. Consequently, lapatinib
must be administered as a large dose (1000-1500 mg/day) to maintain therapeutic drug level at the intended
site. Different nanocarriers have been developed so far to overcome above mentioned problems associated
with lapatinib. These have been further modified for active or passive targeting and for controlled release of
drug over a long period. Human serum albumin based lapatinib nanoparticles were found to have absolute
bioavailability 8-fold higher than tablet form (Wan et al., 2015). Polymeric lipid hybrid nanoparticles
demonstrated a sustained release of the drug for 5 days, which can reduce dose size and frequency (Huo et
al., 2015). Dextran sulfate and chitosan nanoparticles can be of great potential due to their biodegradable
and nontoxic nature (Mobasseri et al., 2017). Modifying polymers using different ions can be helpful to
control particle size distribution, which can also reduce the zeta potential in the negative region thereby
increasing their stability in biological fluid. Most of the nanoformulations for lapatinib studied until now
have been reported as better drug delivery systems compared to Tykerb (marketed tablet dosage form of
lapatinib) in terms of solubility, bioavailability, plasma half-life and toxicity profile which suggest nano
delivery approach as a promising mean for delivery of lapatinib.
Like lapatinib, ketoconazole is also a BCS class II drug with an aqueous solubility of 0.29 mg/mL, variability in
oral adsorption and peak serum concentration (Górniak et al., 2016; Tsume et al., 2018). A very few research
article is available on nanoformulation of ketoconazole and mostly those have been studied were on its
antifungal activity. Its pharmacokinetic profile is similar to lapatinib having 83.7% binding affinity for plasma
protein primarily albumin. 15.3% gets bound to erythrocyte leaving only 1% available as free drug which
significantly compromises its desired action. (Daneshmend and Warnock et al., 1988)
As both lapatinib and ketoconazole share similar kind of profile, they can be given together using a single
vehicle as a nanoformulation for their combined action.
13

Rationale and Hypothesis
Lipid based nanoparticles are the oldest and most widely studied nanocarrier. They can be easily prepared
from natural sources and have the advantages of low toxicity, high loading capacity, thermal and temporal
stability, and low production cost and scalability in manufacturing process. Due to their similarity in structure
with mammalian cell membranes, they exhibit excellent biocompatibility and tissue penetration. This is a
very efficient mean to deliver both hydrophobic and hydrophilic drug which can increase their plasma halflife and duration of action at the target site by controlling the release. They can also be chemically modified
with polyethylene glycol to escape immune reaction and antibodies to give target specificity to recognize
specific receptors in tumor cells.
Due to problems associated with administration of Lapatinib and Ketoconazole, plus the many
different advantages of lipid nanoparticle as a carrier, we have chosen to prepare a lipid-based dual drug
delivery system for lapatinib and ketoconazole combination therapy. In this study, a lipid-based micelle will
be prepared using dioleoylphosphatidylethanolamine (DOPE) and cationic DC cholesterol which will be
further modified using PEGylated hyaluronic acid as a coating (Figure 6). Adding cholesterol in the system
will increase the fluidity and give it a fusogenic property for help passing through the cell membrane.
Hyaluronic acid as a negative coating will reduce the toxicity of system and can also be beneficial for targeting
CD44 receptors overexpressed in tumor cells (Choi et al., 2011). Additionally, polyethylene glycol (PEG) in
hyaluronic acid will help the particle to avoid protein corona formation and to escape getting detected by
macrophages (Moghimi et al., 2003). Hyaluronidase (HAase) present in the tumor extracellular matrix and
lysosomes will degrade the HA coating and unmask the high positive charges of micelle to assist in endosomal
escape and intracellular distribution of the particle (Figure 7). Both drugs will form the inner hydrophobic
core of the micelle. Our hypothesis is that this dual nano drug delivery system will be an effective way to
improve the chemotherapeutic outcome of lapatinib in cancer cells as well as to overcome drug resistance
by surmounting the challenges faced by conventional method.
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Figure 6: Proposed hyaluronic acid coated lipid micellar nanocarrier

Figure 7: Schematic illustration of proposed hyaluronic acid coated lipid micellar nanocarrier for
combined delivery of lapatinib and ketoconazole. Drug delivery includes steps of active targeting of
micelle, degradation of HA coat by HAase at HAase-rich lysosome, lysosomal escape of highly positive
micellar particle in cytoplasm and release of drugs in cancer cells.
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CHAPTER TWO
MATERIALS AND METHODS
Preparation of hyaluronic acid coated lipid nanoparticles
Drug loaded cationic lipid micellar particles were prepared by applying the commonly used thin film
hydration method. Briefly, neutral phospholipid dioleoylphosphatidylethanolamine (DOPE) and DC
cholesterol (Avanti Polar Lipids) were dissolved in a mixture of chloroform and methanol (2:1, v/v) at a 5:2
molar ratio. Then the drugs, lapatinib (LP) and ketoconazole (KC) (molar ratio, 100:67), were added into the
mixture. The organic solvent was then evaporated under vacuum overnight using a rotary evaporator. The
resulting film was then heated for 2 minutes and hydrated with distilled water followed by sonication
(Branson 2510 Sonicator) in a water bath for 6-7 minutes. Free drug and aggregates were removed as by
centrifugation at 2000 G for 5 minutes.
To prepare a hyaluronic acid (HA) (50 kDa, PEG 2 kDa) (Creative PEGWorks) coating on the surface
of the micelles, the prepared micelles were added to prediluted HA solution (1.25 mg/mL) at 100:15 ratio
followed by homogenization using a probe sonicator on ice. Followed by incubating overnight at 4 °C for
ionic interaction. (Figure 8)

Figure 8: Preparation scheme of HA coated lipid micellar particle using the thin-film hydration method.
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Physical characterization of the micellar particle
The morphology of the uncoated and coated micelles were observed using JEOL 1200 EX transmission
electron microscope (TEM) at 80 kV. The particle size, polydispersity, and zeta potential were obtained using
a Malvern Zetasizer. To check the drug encapsulation efficiency (EE) Dionex ultimate 3000 UHPLC was used.
In Brief, micelles were disrupted into a methanol:acetic acid mixture (80:20) and the supernatant was taken
after centrifugation at 5000 rpm for 5 minutes. The amounts of LP and KC were determined by HPLC coupled
with a C18 column at a flow rate of 0.6 mL/min and the absorption wavelength of 254 nm. The mobile phase
for both LP and KC was acetonitrile: water (25:75, v/v) buffered with 0.1% TFA (v/v). The following equations
were used to calculate the encapsulation efficiency and loading capacity of the particles.

% Encapsulation Efficiency EE =

% Loading Capacity LC =

Each Drug in the Particle
X 100
Total Drug Used

Each Drug in the Particle
X 100
Total Lipid Used in the Particle

In vitro drug release study
In vitro drug release study has been done using dialysis method at pH 7.4 and 5 in presence and absence of
hyaluronidase under sink condition. In short, particles equivalent to 600 μg LP and KC each were taken in a
dialysis bag (MWCO: 3.5 - 5 kDa) and immersed in 5 mL of PBS or pH 5 PBS containing 1% tween (incubation
with or without HAase, 0.5 mg) at 37°C and shaken horizontally at 100 rpm. At predetermined time intervals,
0.5 mL of medium was collected and replaced with equal volume of fresh media. Withdrawn sample was
analyzed by HPLC to determine the amount of each drug released.
Cellular uptake
Intracellular uptake of the lipid particles was investigated by fluorescent imaging using Keyence Microscope.
Briefly, fluorescent-labeled lipid particles were synthesized by adding 1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine-N-lissamine rhodamine B sulfonyl (Avanti Polar Lipids) (3% w/w) to the initial lipid
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mixture in chloroform and methanol (2:1) during the preparation of drug loaded micelle. Coating with HA
was done in the similar manner previously described. H1650 cells were seeded in a 96-well plate at a density
of 20,000/well and cultured for 24 hours. Subsequently, cells were incubated with rhodamine lipid particles
for 1, 2, 4, and 6 hours followed by PBS wash, fixation with 10% formalin and DAPI staining. After that
fluorescence intensity was observed at 10X magnification using keyence microscope.
Lung cancer cell lines used in this study
Human lung cancer cell line, H1650 having EGFR mutation and EGFR wild type cell line, LLC have been used
in this study to represent Non-Small Cell Lung Cancer (NSCLC) (Table 2). LLC cells purchased from PerkinElmer
have stable luciferase expression (LLC1).
Table 2: Different Cells used and their EGFR Mutation Status

Generation of lapatinib resistant (DT) cell lines
LLC1 and H1650 cells were grown in DMEM and RPMI 1640 media respectively having the highest static
concentration of lapatinib (LLC1 - 6 μM; H1650 - 7.5 μM) in which they can manage to proliferate for 2
months and used for assays after day 20 (Howell et al., 2020). IC50 of lapatinib for these DT cells was checked
after two months to evaluate the extent of resistance developed.
In vitro cytotoxicity study
The Cell Titer Glo (CTG) assay was used to assess the biocompatibility of blank particle and antitumor efficacy
of drug-loaded particle. In short, for monolayer culture, LLC1 and H1650 cells (both PT & DT) were plated
into 96-well plates at a density of 4 × 103 and 6 x 103 cells/well respectively. Next day after 24 h of incubation
in DMEM (LLC1) and RPMI 1640 (H1650) media, the cells were treated with lipid particles at concentrations
equivalent to 1.25–40 μM of lapatinib or the equivalent amount of free drugs and incubated for 48 h. For 3
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D scaffold culture, a Fiber Inspired Smart Scaffold (FiSS) was prepared and seeded with cells following a
published protocol (Girard et al., 2013; Das et al., 2017). In brief, before plating cells, scaffolds were washed
with ethanol and PBS followed by UV sterilization for 2 hours. Then they were transferred to a 96 well plate
and left in media overnight. The next day, LLC1 cells (PT & DT) were seeded at 3 x 103 cells/well density on
scaffolds and on day 3 tumoroids formation was checked after incubation with nuclear stain nuc blue for an
hour using EVOS microscope. After 3 days or 72 h of incubation in DMEM media, the cells were treated with
lipid particles at concentrations equivalent to 2.5–80 μM of lapatinib or the equivalent amount of free drugs
and incubated for 48 h. At the end of incubation, medium was removed and CTG reagent mixed with media
in 1:1 ratio was added into each well and incubated in a shaker for another half an hour. The luminescence
of each sample was determined by a microplate reader (Bio-Tek Synergy H4 plate reader). The 50% inhibitory
concentration (IC50) was calculated from the nonlinear regression of a dose response curve using GraphPad
Prism software.
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CHAPTER THREE
RESULTS AND DISCUSSION
Preparation and characterization of hyaluronic acid coated lipid nanoparticles
The cationic micelles were prepared using thin film hydration-ultrasonication procedure. Initially four
different molar ratios of DOPE and DC cholesterol have been tired for the micelle. Considering size, charge,
PDI value and encapsulation efficiency, the 5:2 (2.5:1) ratio was chosen to carry on further experiments
which gave the lowest PDI value (0.166) and maximum encapsulation efficiency both for lapatinib (70%) and
ketoconazole (100%). Similarly, for HA coating, different lipid drug to HA ratios have been studied and finally
100:15 has been chosen as a desired composition for having particles with lowest PDI value (0.188) and size
(~170 nm). Zeta potential of the micelle was 40.9 mV which could be attributed to presence of DC cholesterol
in the particle (Table 3). After coating with negatively charged hyaluronic acid zeta potential value showed a
significant reduction to 13 mV (Table 3). This nonnegative charge despite the presence of HA can be
attributed to PEG in HA, which acts as a shield for charge of HA by its outward chain. Usually, cationic lipid
particles show plasma instability due to being aggregated with anionic components of plasma, thus resulting
in rapid clearance from circulation. These particles also have risk of cytotoxicity and unwanted immune
reaction. In contrast, the presence of PEG as a hydrophilic shell will increase plasma stability of this particle
and will reduce its plasma protein interactions and increase circulation half-life of the particle. PEG also
incorporates stealth property in the micelles by helping to get rid of immune recognition by macrophages.
Dynamic light scattering and transmission electron microscopy data show that the size (~ 170 nm)
of the final coated particles has been found to be below 200 nm, which is crucial for the in vivo application
of nano drug delivery and helps to minimize the uptake by phagocytes and to utilize the enhanced
permeation and retention (EPR) effect in tumor site for passive targeting (Figure 9, 10). Moreover, having a
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size of <200 nm is helpful to avoid filtration by kidney and to reduce specific sequestration by fenestra in
liver and sinusoids in the spleen (Duan et al., 2013). TEM image confirmed presence of HA coating around
particles which is apparent as a dark circle around the micelle (Figure 10).
HPLC analysis showed that encapsulation of lapatinib in the HA particle was 70% and 100% for
ketoconazole (Figure 11). This high percentage of encapsulation is very important, for drugs like lapatinib
which have low potency, to minimize unwanted burden of carrier components in the formulation.

Table 3: Characteristics of different micellar and HA coated particles.
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A

B

Figure 9: Size and zeta potential of (A) uncoated and (B) HA coated particles using dynamic light
scattering. (Mean ± SD, N = 3)
A

B

μm

Figure 10: Transmission electron microscopy (TEM) images of (A) uncoated particle, (B) HA-coated
particle. Scale bar represents 1 μm.

22

A

B

C

Figure 11: (A) Standard curve of lapatinib and ketoconazole measured using HPLC. (B) Encapsulation
efficiency and (C) Loading capacity of HA particle. N = 3
In vitro drug release study
In vitro release kinetic experiments of lapatinib and ketoconazole loaded HA particles were performed for a
period of 96 hours in PBS, pH 7 and 5, at 37°C in presence and absence of hyaluronidase. In absence of HAase
drug the data showed two phase release profile, with initial fast release up to 24 hours followed by a slow
and steady release later up to 96 hours. Cumulative release of lapatinib and ketoconazole was 41% and 33%
at pH 7 in 96 hours which was slightly increased to 50% and 37% at pH 5 (Figure 12). Additionally, both drugs
showed an initial burst release in presence of HAase which continued till first 10 hours for lapatinib and 24
hours for ketoconazole in pH 7 and pH 5 conditions. After those time periods, drug release went on slowly
which ended up to 37% and 26% at pH 7 and 35% and 28% at pH 5 for lapatinib and ketoconazole respectively
(Figure 4). These results suggest that both pH change and HAase presence have an effect on drug release.
Overall, this formulation showed very slow drug release pattern which can be attributed to the shielding and
protective effect of the membrane due to presence of PEG (Lasic et al., 1997). Usually, drugs with greater
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lipophilicity show a slow release profile instead of a premature release (Gulati et al., 1998). These
phenomena can be beneficial for drugs to be delivered at target site without being released during systemic
circulation.

A

B

Figure 12: A) In vitro drug release from HA drug particles at pH 7 and 5; (B) In vitro drug release from HA
drug particles after incubation with HAase (0.5 mg/mL) at pH 7 and 5; both calculated as a percentage of
total encapsulated drugs. Blank HA particle was used as control. N = 1.

Cellular uptake
Efficient cellular uptake of nanoformulations is mandatory for the drugs to be delivered intracellularly. In
order to investigate cell uptake of HA coated particles, H1650 cells were incubated with rhodamine labeled
drug loaded HA particle for 1, 2, 4, and 6 hours. The fluorescent signal in fixed cells was measured using a
Keyence microscope. Fluorescence intensity of the rhodamine particle increased over the incubation time
period and reached strongest at 6 h calculated using ImageJ, implying a time-sensitive cellular uptake and
efficient drug delivery to cytoplasm (Figure 13).
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A

B

Figure 13: (A) Cellular uptake of rhodamine labeled HA particle in H1650 cells; N = 3; *P < .05, **P < .01,
***P < .001, ****P < .0001. ANOVA and the Tukey post hoc test were used to calculate
the significance. (B) Fluorescence microscopy images (10x magnification) of H1650 cells after incubation
with 50 μg/mL of rhodamine labeled HA-particle for different time periods; 1, 2, 4, 6 hours. Scale bar
represents 500 μm.
In vitro cytotoxicity study
Lapatinib resistance in H1650 and LLC1 cells has been evaluated using CTG assay which confirmed
development of resistance and its extent after culturing in presence of lapatinib for 2 months. H1650 drug
tolerant (DT) cells (IC50 44 μM) developed showed ~3 folds increase in IC50 value of lapatinib than parental
(PT) cells (IC50 13 μM). On the other hand, LLC1 drug tolerant (DT) cells (IC50 13.8 μM) showed ~2 folds
increase in IC50 value than parental (PT) cells (IC50 23 μM) (Figure 14).
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Figure 14: H1650 and LLC1 parental (PT) and resistant (DT) cells were treated with different
concentrations of lapatinib (range 1.25 μM to 40 μM) for 48 hours and cell viability was assessed using
Cell Titer Glo (CTG) assay, N = 3.
Cytotoxic activity of the drug loaded HA particle has been investigated against H1650 and LLC1
(monolayer and scaffold) cell lines using both parental and lapatinib resistant cells. IC50 data revealed that
HA particles showed same as or in some cases more effectivity than free drugs after 48 hours of treatment
as expected. Briefly in case of H1650 cells, IC50 of free drugs was 12 μM and of HA particles was 9 μM for
parental cells and for drug tolerant cells IC50 was 13 μM and 9 μM respectively. Regarding LLC1 monolayer
cells, IC50 of free drugs was 10 μM and of HA particles was 8.5 μM for parental cells and for drug tolerant
cells IC50 was 7 μM for both. And with respect to LLC1 tumoroids, IC50 of free drugs was 21 μM and of HA
particles was 19 μM for parental cells and for drug tolerant cells IC50 was ~60 μM for both free drugs and HA
particles. (Figure 7) Scaffold mimics extra cellular matrix (ECM) surrounding cells in tumor microenvironment
which provides support and attachment surface for tumoroid formation. 3 D tumoroids are better in vitro
tumor model than 2 D monolayer assay and much more relatable to in vivo environment of cancer where
cells behave very differently in presence of ECM than monolayer culture. (Rijal and Li, 2017). Above results
also support this phenomenon where in LLC1 monolayer IC50 of HA particle has been found to be 8.5 μM
which was increased to 60 μM in LLC1 tumoroids. (Figure 15 and 16, Table 4)
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A

B

C

Figure 15: Viability of (A) H1650, (B) LLC1 (monolayer), (C) LLC1 (scaffold) both parental (PT) and resistant
(DT) cells treated with free Lapatinib Ketoconazole (LPKC) and drug loaded HA particles for 48 hours
having concentrations of both Lapatinib and Ketoconazole ranging from 1.25 μM to 40 μM, N = 3.
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Table 4: Comparison of IC50 of free drugs and HA particles in different cell lines

Figure 16: Comparison of IC50 of free drugs and HA particles in different cell lines, *P < .05, N = 2. An
unpaired t-test has been used to analyze the significance.
The biocompatibility of the blank HA particles has been assessed against H1650 and LLC1 cell lines
using CTG assay. As shown in figure 17, the cell viability was higher than 80% with the concentration of blank
particle up to 42.5 μg/mL for both cell lines, which indicated a sound biocompatibility of the nanocarrier.
Here, 170 μg/mL blank particle is corresponding to 40 μM lapatinib in HA particle which means to reach the
IC50 of drug particle ~42.5 μg/mL blank particle is needed in both H1650 and LLC1 cells. (Figure 17)
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Figure 17: In vitro cytotoxicity of blank HA particles in H1650 and LLC1, N = 3. H1650 and LLC1 cells were
incubated with different concentrations of Blank HA particles for 48 hours and cell viability was
analyzed. *P < .05, ****P < .0001. ANOVA and the Tukey post hoc test were used to analyze
the significance.
Presence of hyaluronic acid as a coating around the micelle has a significant effect in reducing the
toxicity of this cationic micellar nanocarrier which otherwise has shown substantial toxicity while comparing
the biocompatibility of uncoated and HA coated blank particle in H1650 cells. As shown in figure 18, around
the IC50 concentration of HA drug particle, uncoated blank particle possesses 50 % cell viability compared to
90 % viability for coated blank particle which further implied the biocompatibility of this hyaluronic acid
coated lipid micellar particle.
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Figure 18: Comparison of IC50 of uncoated and HA coated blank particle in H1650 cell line. H1650 cells
were incubated with different concentrations of Blank uncoated and HA coated particles for 48 hours
and cell viability was obtained using Cell Titer Glo (CTG) assay, N = 3. *P < .05, **P < .01, ***P < .001. An
unpaired t-test has been used to analyze the significance.

Statistics
Most of the experiments have been repeated twice or more in this study. Statistical significance for each
experiment was calculated using t test when comparing just two groups. Analysis of Variance (ANOVA) was
performed while comparing multiple groups and for comparing the mean of each group with the mean of
every other group, the Tukey post hoc test has been done. *P < .05, **P < .01, ***P < .001, ****P < .0001.
GraphPad Prism 8.0 software has been used in all calculations and plotting graphs.
Acknowledgement: All illustrations in this paper have been created with the help of BioRender.com.
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CHAPTER FOUR
CONCLUSION AND FUTURE DIRECTIONS
In this study, HA coated lipid micellar particle for co-delivery of lapatinib and ketoconazole has been
successfully prepared. This particle displayed a string of attractive properties, including ease of preparation,
narrow size distribution, high drug loading capacity, biocompatibility, time dependent cellular uptake and
release profile, desirable cytotoxicity towards cancer cells which are extremely valuable for an anticancer
drug delivery vehicle. Cytotoxicity profile of the HA drug particle was 25% higher than free drugs in H1650
for both PT and DT cells. In case of LLC1, it showed 10% higher activity than free drugs in PT and similar affect
as free drugs in DT cells. All the lipids used in this nanocarrier are FDA approved and have been studied
extensively for drug delivery before that verifies the safety profile of this carrier (Barenholz et al., 2012,
Caplenet al., 1995). Thus, HA coated lipid micellar particles can be an efficient way to improve systemic
exposure and to prolong the circulation of lipophilic drugs like lapatinib and ketoconazole.
In this instance, chemotherapeutic efficacy of this dual drug particle has been estimated using lung cancer
model. As lapatinib is an FDA approved drug for treatment of advanced breast cancer, that can be a future
target to evaluate the functionality of this nanocarrier for lapatinib and ketoconazole delivery. In vivo antitumor efficacy can also be performed to assess its broader applicability. Besides, it can be a potential tool
for drug and gene co delivery in cancer cells with the help of cationic lipid part of the system which is a
popular strategy in current gene delivery approaches.
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